FR3004650B1 - Composition topique comprenant un variant d'une protéine sauvage à pli-OB, ainsi que son procédé de préparation - Google Patents

Composition topique comprenant un variant d'une protéine sauvage à pli-OB, ainsi que son procédé de préparation

Info

Publication number
FR3004650B1
FR3004650B1 FR1353662A FR1353662A FR3004650B1 FR 3004650 B1 FR3004650 B1 FR 3004650B1 FR 1353662 A FR1353662 A FR 1353662A FR 1353662 A FR1353662 A FR 1353662A FR 3004650 B1 FR3004650 B1 FR 3004650B1
Authority
FR
France
Prior art keywords
wild
variant
well
preparation process
topical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1353662A
Other languages
English (en)
French (fr)
Other versions
FR3004650A1 (fr
Inventor
Olivier Kitten
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AFFILOGIC
Original Assignee
AFFILOGIC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1353662A priority Critical patent/FR3004650B1/fr
Application filed by AFFILOGIC filed Critical AFFILOGIC
Priority to JP2016509434A priority patent/JP2016518379A/ja
Priority to US14/786,287 priority patent/US10548945B2/en
Priority to CN202010402321.XA priority patent/CN111467477A/zh
Priority to PCT/EP2014/058139 priority patent/WO2014173899A1/fr
Priority to CN201480030115.3A priority patent/CN105338995B/zh
Priority to EP14718621.7A priority patent/EP2988766B1/fr
Priority to ES14718621.7T priority patent/ES2637421T3/es
Publication of FR3004650A1 publication Critical patent/FR3004650A1/fr
Application granted granted Critical
Publication of FR3004650B1 publication Critical patent/FR3004650B1/fr
Priority to JP2019022358A priority patent/JP2019112410A/ja
Priority to US16/726,305 priority patent/US10898542B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Peptides Or Proteins (AREA)
FR1353662A 2013-04-22 2013-04-22 Composition topique comprenant un variant d'une protéine sauvage à pli-OB, ainsi que son procédé de préparation Expired - Fee Related FR3004650B1 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
FR1353662A FR3004650B1 (fr) 2013-04-22 2013-04-22 Composition topique comprenant un variant d'une protéine sauvage à pli-OB, ainsi que son procédé de préparation
ES14718621.7T ES2637421T3 (es) 2013-04-22 2014-04-22 Composiciones tópicas que comprenden variantes de pliegue-OB
CN202010402321.XA CN111467477A (zh) 2013-04-22 2014-04-22 包含pli-ob变体的局部组合物
PCT/EP2014/058139 WO2014173899A1 (fr) 2013-04-22 2014-04-22 Compositions topiques comprenant des variantes de pli-ob
CN201480030115.3A CN105338995B (zh) 2013-04-22 2014-04-22 包含pli-ob变体的局部组合物
EP14718621.7A EP2988766B1 (fr) 2013-04-22 2014-04-22 Compositions topiques comprenant des variantes de pli-ob
JP2016509434A JP2016518379A (ja) 2013-04-22 2014-04-22 Ｏｂフォールド変異体を含む局所用組成物
US14/786,287 US10548945B2 (en) 2013-04-22 2014-04-22 Topical compositions comprising OB-fold variants
JP2019022358A JP2019112410A (ja) 2013-04-22 2019-02-12 Ｏｂフォールド変異体を含む局所用組成物
US16/726,305 US10898542B2 (en) 2013-04-22 2019-12-24 Topical compositions comprising OB-fold variants

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1353662A FR3004650B1 (fr) 2013-04-22 2013-04-22 Composition topique comprenant un variant d'une protéine sauvage à pli-OB, ainsi que son procédé de préparation

Publications (2)

Publication Number Publication Date
FR3004650A1 FR3004650A1 (fr) 2014-10-24
FR3004650B1 true FR3004650B1 (fr) 2015-05-29

Family

ID=48795734

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1353662A Expired - Fee Related FR3004650B1 (fr) 2013-04-22 2013-04-22 Composition topique comprenant un variant d'une protéine sauvage à pli-OB, ainsi que son procédé de préparation

Country Status (7)

Country Link
US (2) US10548945B2 (enExample)
EP (1) EP2988766B1 (enExample)
JP (2) JP2016518379A (enExample)
CN (2) CN111467477A (enExample)
ES (1) ES2637421T3 (enExample)
FR (1) FR3004650B1 (enExample)
WO (1) WO2014173899A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3004650B1 (fr) * 2013-04-22 2015-05-29 Affilogic Composition topique comprenant un variant d'une protéine sauvage à pli-OB, ainsi que son procédé de préparation
FR3027521B1 (fr) * 2014-10-24 2016-12-16 Affilogic Compositions pour administration par voie orale
EP3483180A1 (en) * 2017-11-14 2019-05-15 Affilogic Multi specific molecules
EP3632924A1 (en) 2018-10-07 2020-04-08 Affilogic Binders for inhibiting formation of multimeric proteins
WO2020231504A1 (en) 2019-05-16 2020-11-19 Massachusetts Institute Of Technology Glycan-binding proteins and related compositions and methods
EP3878858A1 (en) 2020-03-11 2021-09-15 Affilogic Variants of sac7d and their use in cancer therapy
EP4043481A1 (en) 2021-02-15 2022-08-17 Affilogic Compounds and methods for extending half life of biomolecules
JP2024513711A (ja) 2021-03-18 2024-03-27 アフィロジック 抗ｃ３因子ｓａｃ７ｄバリアントおよびその補体介在性障害を治療するための医学的使用
EP4059949A1 (en) 2021-03-18 2022-09-21 Affilogic Anti-factor c3 sac7d variants and their medical use for treating complement-mediated disorders
CN117106745B (zh) * 2022-06-01 2025-02-14 北京擎科生物科技股份有限公司 逆转录突变体及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030228616A1 (en) * 1999-10-29 2003-12-11 Stratagene DNA polymerase mutants with reverse transcriptase activity
EP2029620B1 (en) * 2006-05-26 2016-05-25 Waikatolink Limited Ob fold domains
ATE542830T1 (de) * 2006-12-04 2012-02-15 Pasteur Institut Als gerüst verwendeter ob-fold zur entwicklung neuer spezifischer bindemittel
ES2836948T3 (es) * 2008-11-03 2021-06-28 Molecular Partners Ag Proteínas de unión que inhiben la interacción del receptor de VEGF-A
US20110098216A1 (en) * 2009-10-22 2011-04-28 Regen Therapeutics Plc Therapeutic uses of colostrinin
EP2469278A1 (en) * 2010-12-21 2012-06-27 Institut Pasteur Reagentless fluorescent biosensors from nanofitins, rational design methods to create reagentless fluorescent biosensors and methods of their use
FR2974816A1 (fr) * 2011-05-04 2012-11-09 Centre Nat Rech Scient Methode de generation de proteines
FR3004650B1 (fr) * 2013-04-22 2015-05-29 Affilogic Composition topique comprenant un variant d'une protéine sauvage à pli-OB, ainsi que son procédé de préparation
FR3027521B1 (fr) * 2014-10-24 2016-12-16 Affilogic Compositions pour administration par voie orale
PL412787A1 (pl) * 2015-06-22 2017-01-02 Magdalena Król Oparty na makrofagach celowany system dostarczania związków związanych z ferrytyną
US20190167576A1 (en) * 2016-09-08 2019-06-06 The Board Of Trustees Of The Leland Stanford Junior University Use of high affinity monoclonal antibody product binders to increase the duration of action of therapeutic monoclonal antibody products in a biologic tissue
EP3483180A1 (en) * 2017-11-14 2019-05-15 Affilogic Multi specific molecules
EP3632924A1 (en) * 2018-10-07 2020-04-08 Affilogic Binders for inhibiting formation of multimeric proteins
EP3878858A1 (en) * 2020-03-11 2021-09-15 Affilogic Variants of sac7d and their use in cancer therapy
EP4059949A1 (en) * 2021-03-18 2022-09-21 Affilogic Anti-factor c3 sac7d variants and their medical use for treating complement-mediated disorders

Also Published As

Publication number Publication date
WO2014173899A1 (fr) 2014-10-30
CN105338995B (zh) 2020-06-09
FR3004650A1 (fr) 2014-10-24
US10898542B2 (en) 2021-01-26
ES2637421T3 (es) 2017-10-13
JP2016518379A (ja) 2016-06-23
CN111467477A (zh) 2020-07-31
US10548945B2 (en) 2020-02-04
US20160143990A1 (en) 2016-05-26
JP2019112410A (ja) 2019-07-11
US20200138899A1 (en) 2020-05-07
EP2988766B1 (fr) 2017-06-07
EP2988766A1 (fr) 2016-03-02
CN105338995A (zh) 2016-02-17

Similar Documents

Publication Publication Date Title
FR3004650B1 (fr) Composition topique comprenant un variant d'une protéine sauvage à pli-OB, ainsi que son procédé de préparation
CL2016000221A1 (es) Anticuerpos anti-fgfr2iiib afucosilados.
CO2017013229A2 (es) Agonistas de receptor de apelina (apj) de 4-hidroxi-3-(heteroaril)piridin-2-ona como para uso en el tratamiento de trastornos cardiovasculares
BR112015022095A2 (pt) formulações eutéticas de cloridrato de ciclobenzaprina e cloridrato de amitriptilina
EP3302275A4 (en) WELDING DISPLAY OF PHYSIOLOGICAL CONDITIONS
BR112015016585A2 (pt) Compostos radiofarmacêuticos baseados em triazina, complexos de metal e composição farmacêutica compreendendo os referidos complexos
BR112016002391A2 (pt) composições tópicas e métodos de uso das mesmas
EA201691259A1 (ru) РЕГУЛЯТОРЫ Nrf2
BR112016007065A2 (pt) composto, composição, utilização de um composto e método para o controle da vegetação
MX2017012699A (es) Compuestos heterociclicos como inhibidores de demetilasa 1 especifica de lisina (lsd1).
BR112016006527A2 (pt) composto, composição, utilização de um composto e método para o controle da vegetação
EP2964208A4 (en) TOPICAL USE OF ANTIMICROBIC FORMULATION
EP2968269A4 (en) PROCESS FOR THE PREPARATION OF BETA-3-AGONISTS AND INTERMEDIATE PRODUCTS THEREOF
BR112016028476A2 (pt) compostos, composição, utilização de um composto, método para o combate dos fungos nocivos e sementes
EA201591805A1 (ru) Оксабицикло [2.2.2] кислоты - модуляторы gpr120
HUE044737T2 (hu) Alzheimer-kór szubpopulációk kezelése egyesített immunglubulin G-vel
EA201590951A1 (ru) Дигидропиразольные модуляторы gpr40
EP3040328A4 (en) NEW SALVIANOLIC ACID COMPOUND T, METHOD OF MANUFACTURING THEREOF AND USE THEREOF
EA201590954A1 (ru) Дигидропиразольные модуляторы gpr40
BR112015031913A2 (pt) processo para a fabricação de amino-benzoxazinonas 4-propargilatadas e sua utilização
EA201590949A1 (ru) Дигидропиразольные модуляторы gpr40
EP3592371A4 (en) STABILIZED PROTEIN-LINKED CANNABINOID COMPOSITIONS
BR112015016194A2 (pt) compostos, composição, utilização de um composto, método para o combate dos fungos nocivos e semente revestida
CL2015001881A1 (es) Compuesto 4-hidroxi-2-metil-5-(propan-2-iliden)ciclohexil-3-en-1-carbaldehido; uso del compuesto para el tratamiento de la enfermedad de alzheimer; composición farmacéutica; método para preparar la composición.
CO6831981A2 (es) Productos médicos para uso en enfermedades relacionadas con infecciones microbianas en el tracto aerodigestivo superior

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

CA Change of address

Effective date: 20170918

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

ST Notification of lapse

Effective date: 20201205